Estimaciones de analistas de Wall Street para Mirum Pharmaceuticals, Inc. (MIRM): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 1 |
| Compra | 17 |
| Mantener | 0 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 18 |
| Calificación media (1-5) | 1.06 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-03 | $-0.53 | ||
| 2026-08-05 | $-1.06 | $-0.74 | -42.8% |
| 2026-05-06 | $-13.43 | $-0.40 | -3257.5% |
| 2026-02-25 | $-0.11 | $0.02 | -650.0% |
| 2025-11-04 | $0.05 | $-0.10 | +150.0% |
| 2025-08-06 | $-0.12 | $-0.31 | +61.3% |
| 2025-05-07 | $-0.30 | $-0.39 | +23.1% |
| 2025-02-26 | $-0.49 | $-0.27 | -81.5% |
Ratios de valoración
| Precio / Valor contable | -565.87 |
| EV / EBITDA | -7.92 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | $19.1M | $77.1M | $186.4M | $336.9M | $521.3M |
| Coste de Ventas | 0 | $324000 | $623000 | $1.9M | $12.4M | $47.0M | $81.6M | $100.6M |
| Beneficio Bruto | 0 | -$324000 | -$623000 | $17.2M | $64.7M | $139.3M | $255.2M | $420.7M |
| I+D | $2.3M | $43.0M | $81.6M | $131.4M | $106.8M | $102.6M | $140.6M | $186.2M |
| Generales y Administrativos | $585000 | $11.8M | $22.7M | $59.2M | $89.1M | $145.9M | $202.2M | $257.0M |
| Gastos Operativos | $2.9M | $54.7M | $103.7M | $190.6M | $195.9M | $248.5M | $342.9M | $443.2M |
| Beneficio Operativo | -$2.9M | -$54.7M | -$104.3M | -$173.4M | -$131.2M | -$109.2M | -$87.6M | -$22.1M |
| EBITDA | -$17.3M | -$52.2M | -$102.3M | -$65.4M | -$122.9M | -$136.5M | -$49.0M | $17.2M |
| Gastos por Intereses | 0 | 0 | $335000 | $17.6M | $16.0M | $15.1M | $14.3M | $14.4M |
| Beneficio Antes de Impuestos | -$17.3M | -$52.5M | -$103.3M | -$84.0M | -$142.1M | -$162.4M | -$86.9M | -$21.4M |
| Impuestos | 0 | $21000 | $6000 | $37000 | -$6.4M | $991000 | $1.0M | $1.9M |
| Beneficio Neto | -$17.3M | -$52.6M | -$103.3M | -$84.0M | -$135.7M | -$163.4M | -$87.9M | -$23.4M |
| BPA | $-0.75 | $-2.29 | $-4.09 | $-2.77 | $-4.01 | $-4.00 | $-1.85 | $-0.47 |
| BPA Diluido | $-0.75 | $-2.29 | $-4.09 | $-2.77 | $-4.02 | $-4.00 | $-1.85 | $-0.47 |
| Acciones en Circulación (Diluidas) | $23.0M | $23.0M | $25.3M | $30.3M | $34.0M | $40.9M | $47.5M | $50.2M |
Precio
| Precio | $97.37 |
| Capitalización | $5.9B |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ACAD · ADMA · BLTE · DYN · LGND · PRAX · RARE
Explorar sector: Healthcare · Biotechnology
Más secciones de MIRM: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones